Press Release Celdara Medical, LLC today announced that the National Cancer Institute of the National Institutes of Health (NIH) has awarded a Small Business Innovation Research (SBIR) Phase I award to fund the company’s proof of concept studies on a new platform to improve chimeric antigen receptor (CAR) T cells […]
February 22, 2022 – Celdara Medical, LLC today announced that alumni of their DRIVEN Partnership Program have collectively surpassed $50M in follow-on funding. DRIVEN was established in 2018 as the Northeast’s NIH-funded Accelerator Hub. Led by Celdara Medical and Simbex, it has always had a singular goal: improve human health […]
January 26, 2022 – Aclys Bio Corp (“Aclys”), a company discovering and developing precision biologics for the treatment of cancer, earlier this month announced a new exclusive research and commercial license option agreement with Genmab A/S (Nasdaq: GMAB), an international biotech company specializing in the creation and development of differentiated […]
Celdara Medical, LLC today announced the awarding of six DRIVEN Accelerator Hub grants to outstanding researchers and innovators in the Northeast region. In this most recent round of funding, two Acceleration Awards (up to $50,000 per early-stage company) were awarded to Olfax Medical (Vermont) and ResusciTech (Rhode Island) and 4 Ignition Awards (up to $25,000 per faculty innovator) were awarded to Andre Khalil, PhD (University of Maine), Gian Ignacio, MD Candidate (Brown), Michael Cole, PhD (Dartmouth), and Yina Huang, PhD (Dartmouth).
Celdara Medical, LLC today announced the selection of five outstanding researchers as the recipients of the 2021 Celdara Medical High-Potential Entrepreneurs’ Fellowships (CHEF). The program provides a part-time, year-long experiential learning opportunity at Celdara to senior graduate students and post-doctoral researchers. Fellows receive an opportunity to hone their executive skills […]
Joana Murad Mabaera, Executive Director of R&D Expertise: Cellular Therapies and Molecular Biomarkers What are your professional interests & in what ways does Celdara help you engage those interests? My core professional interest is translational science. At Celdara Medical, I help build the foundation for the development of […]
ImmuType™ is a Celdara Medical Enterprise focused on providing improved care for patients with systemic autoimmune disease. By supporting patient stratification and identifying treatment responders based on each patient’s unique molecular profile, ImmuType™ can improve the success rate, while reducing time and cost of clinical trials. Beyond enrollment, ImmuType™ can […]
Celdara Medical, LLC today announced that the National Cancer Institute (NCI) of the National Institutes of Health (NIH) has awarded a three-year Small Business Innovation Research (SBIR) Fast-Track award to fund the company’s advancement of CM-CX1, a chimeric antigen receptor (CAR) T cell therapy for the treatment of ovarian clear […]
Supported by Celdara Medical and named after its co-founder, the new building and STEM lab is designed for authentic, experiential learning and serves as an exemplary partnership for the future of STEM education LEBANON, N.H. – August 26, 2021 — Celdara Medical, LLC (Celdara), The New Hampshire Academy of Science […]
Celdara Medical, LLC (“Celdara”) announced today the addition of Antonito T. Panganiban, Ph.D., to the Pandemic Security Initiative’s Scientific Advisory Board (SAB), a group of outstanding scientists and infectious disease experts who will advise the Pandemic Security Initiative as it seeks to protect the nation from future pandemics. The SAB […]